Phase 4 N=1,366 VERtebral Fracture Treatment Comparisons in Osteoporotic Women
Postmenopausal Osteoporosis
Primary: Proportion of Participants With New Vertebral Fractures — 28; 64 Participants (with at least one event) — p=0.000094
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=29 Secondary Prevention of Osteoporosis
Osteoporosis
Primary: Number Adherent With the Intervention — 29 participants
Phase 4 N=13 Fracture (FX) Improvement With Teriparatide: FiX-IT Study
Osteoporosis · Atypical Femoral Fracture
Primary: Radiologic Evidence of Bone Healing — 12.6; 11.2; 15.4; 13.2 units on a scale
Phase 3 N=1,262 Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis
Osteoporosis
Primary: Incidence of New or Worsening Vertebral Fractures in Osteoporotic Subjects Treated With Denosumab Compared to Placebo — 3.6; 10.3; 7.2 Vertebral fractures — p=0.0001
Phase 3 N=131 Vertebroplasty for the Treatment of Fractures Due to Osteoporosis
Spinal Fractures · Osteoporosis
Primary: Back-specific Functional Status Using Roland-Morris Disability Questionnaire (RDQ) Scale at 1 Month — 12.0; 13.0 units on a scale — p=0.49
Phase 4 N=310 Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)
Osteoporotic Fractures · Osteoporosis, Postmenopausal
Primary: Non-traumatic Incidental Fractures (Vertebral and Nonvertebral [Identified by X-ray, CT, MRI, VFA Imaging] Per Person-year) — 1.06093; 1.01563 Fractures per person-year…
Phase 2 N=35 PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial
Osteoporotic Fractures
Primary: Number of Participants With Evidence of Cortical Bridging for Fracture Healing — 9; 8 Participants
Phase 3 N=122 Effect of Teriparatide on Hip Fracture Healing
Femur Neck Fracture
Primary: Percentage of Participants With No Revision Surgery at 12 Months After Internal Fixation of a Low-Trauma Femoral Neck Fracture — 87; 86 percentage of participants
N/A N=1,011 Point-of-care Osteoporosis Diagnostics With Bindex® Pocket Size Instrument and FRAX
Osteoporosis
Primary: Sensitivity of the Density Index Against Dual Energy X-ray Absorptiometry for Detecting Osteoporosis — 93.7; 100 percentage of true positives
N/A N=1,100 A 5-Year Follow-up Study Investigating Factors Associated With Osteoporotic Fracture in Chinese Postmenopausal Women
Osteoporotic Fractures · Osteoporosis, Postmenopausal
Primary: Non-vertebral Fracture Incidence — 70; 0 participants
Phase 3 N=39 Second Study of the Effect of Teriparatide on Hip Fracture Healing
Femur Neck Fracture
Primary: Percentage of Participants With No Revision Surgery at 12 Months After Internal Fixation of a Low-Trauma Femoral Neck Fracture — 74; 93 Percentage of participants
N/A N=2,684 A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care
Osteoporosis
Primary: Number of Participants That Initiate an Osteoporosis Prescription Medication — 157; 153 Participants
Phase 3 N=22 Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women
Menopause · Fracture · Osteoporosis
Primary: Change in Lumbar Spine Bone Density by Dual Energy X-ray Absorptiometry (DXA) — 10.8 percentage of BMD change
N/A N=141 Build Better Bones With Exercise
Osteoporotic Fractures · Spinal Fractures
Primary: Feasibility of Recruitment and Retention — 66; 64 Participants
N/A N=181 Zoledronic Acid for Osteoporosis in the Elderly
Osteoporosis · Bone Loss · Fragility Fractures
Primary: Bone Mineral Density (BMD) of the Total Hip and Spine — 4.5; 0.7; 3.0; 1.1 Percent change
Phase 2 N=41 Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women
Adult Idiopathic Generalized Osteoporosis
Primary: Change in Lumbar Spine Bone Mineral Density (LS-BMD) on Active Medication — 10.1; 4.1 percentage of change
N/A N=89 Study of Effect of Exercise With Osteoporosis and Vertebral Fracture
Osteoporosis · Vertebral Fracture
Primary: Time Used to Walk 20 m at Maximal Speed. — 14.9; 14.7; 13.4; 15.2 Seconds
Phase 4 N=53 Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
Osteopenia · Osteoporosis
Primary: Mean % Change From Baseline in Trabecular Number (Tb.N) by HR-pQCT — 2.1; -0.6; 0.9; 4.1 Percent change
Phase 4 N=33 µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis
Osteoporosis, Osteopenia
Primary: Percentage of Change in Trabecular Surface-to-curve Ratio — 9.1; 7.1 Percentage of Change
Phase 2 N=10 Healthy Body, Healthy Bones After Bariatric Surgery Trial
Bariatric Surgery Candidate · Bone Loss · Bone Resorption
Primary: Change in Hip Bone Mineral Density (BMD) — 0; -.03 g/cm2
Phase 2 N=80 Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
Postmenopausal Osteoporosis · Osteoporosis
Primary: Changes in Indices of Bone Turnover — 4418; 3696; 956; 822 months*(ng/ml - baseline ng/ml)
N/A N=86 Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index
Osteoporosis · Bone Fracture
Primary: Proportion of Change in Mean Trabecular Bone Score — .00238 Proportion of change
N/A N=11 Alendronate in Juvenile Osteoporosis
Juvenile Osteoporosis · Low Bone Density · Fractures
Primary: Bone Mineral Density (BMD) of the Lumbar Spine (Participants With Percentage Increase). — 11 participants
Phase 3 N=712 Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis
Osteoporosis, Postmenopausal · Back Pain · Spinal Fracture
Primary: Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 6-Month Endpoint — 206; 193; 142; 143 participants — p=0.642
Phase 3 N=428 Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis
Osteoporosis
Primary: Change From Baseline at 18 Month Endpoint in Lumbar Spine Bone Mineral Density (BMD) — 0.059; 0.028 grams per square centimeters — p=<0.001
Phase 3 N=407 Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)
Osteoporosis
Primary: Change in Lumbar Spine BMD From Start of Trial Period III Until End of Trial Period III. — 1.002; 0.990 Percentage Change — p=0.010
Phase 2 N=241 Adding Phosphorus to Osteoporosis Drug Treatment
Osteoporosis · Osteopenia
Primary: Lumbar Spine and Hip BMD, Measured as Grams Per Square Centimeter. — 0.76; 0.78; 0.88; 0.86 g/cm2
Phase 3 N=2,463 Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women
Osteoporosis · Postmenopausal Osteoporosis
Primary: Number of Participants With New Vertebral Fractures at 18 Months — 30; 4; 6 participants — p=<0.0001
Phase 3 N=16 Prospective Biomarkers of Bone Metabolism in Hemophilia A
Hemophilia · Bone Disease
Primary: Bone Biomarker Density (BMD) — -0.74; -0.16; -0.16 Z-Score
Phase 4 N=140 Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment
Osteoporosis
Primary: Bone Mineral Density (BMD) at Lumbar Spine (L1-L4) — 5.54; 5.39 percent